CancerDrs

Prostate Cancer clinical trials in Iowa

11 actively recruiting prostate cancer trials at 17 sites across Iowa.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Academic/Other

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …

Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Iowa:
  • McFarland Clinic - Ames — Ames, Iowa
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

This phase III trial compares the effect of adding carboplatin to the standard of care chemotherapy drug cabazitaxel versus cabazitaxel alone in treating prostate cancer that keeps growing even when the amount of testosterone in the body i…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06470243
Sites in Iowa:
  • Mercy Hospital — Cedar Rapids, Iowa
  • Oncology Associates at Mercy Medical Center — Cedar Rapids, Iowa
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

This randomized phase III trial examines whether lengthening the dosage interval in an adaptive manner for the prostate cancer drug lutetium 177 Lu PSMA RLT improves quality of life without decreasing lifespan when compared to the standard…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07200830
Sites in Iowa:
  • Mary Greeley Medical Center — Ames, Iowa
  • McFarland Clinic - Ames — Ames, Iowa
  • UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
  • McFarland Clinic - Boone — Boone, Iowa
  • Saint Anthony Regional Hospital — Carroll, Iowa
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in combination with best supportive care (BSC) as compared to placebo with…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07164443
Sites in Iowa:
  • University of Iowa Hospital and Clinics — Iowa City, Iowa
  • Mission Cancer Blood — Waukee, Iowa
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Iowa:
  • Mary Greeley Medical Center — Ames, Iowa
  • McFarland Clinic - Ames — Ames, Iowa
  • UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
  • University of Iowa Healthcare Cancer Services Quad Cities — Bettendorf, Iowa
  • McFarland Clinic - Boone — Boone, Iowa
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

The purpose of the study is to evaluate the safety, tolerability, and efficacy of the two different treatment combinations of tulmimetostat in participants with de novo or recurrent Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT07190300
Sites in Iowa:
  • Uni Of Iowa Hospitals And Clinics — Iowa City, Iowa
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic …

Sponsor: Orano Med Theranostics, SAS
NCT ID: NCT05283330
Sites in Iowa:
  • University of Iowa Health Care — Iowa City, Iowa
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Iowa:
  • Mary Greeley Medical Center — Ames, Iowa
  • McFarland Clinic - Ames — Ames, Iowa
  • UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
  • McFarland Clinic - Boone — Boone, Iowa
  • Mercy Hospital — Cedar Rapids, Iowa
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Iowa:
  • Massive Bio SYNERGY-AI site — Iowa City, Iowa
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-17